Compare Moderna, Inc. (MRNA) vs iShares Semiconductor ETF (SOXX) Price & Performance

Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.

The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.

SOXX, the iShares Semiconductor ETF, trades at $528.40, up 1.64% on the day, reflecting strong momentum driven by AI infrastructure demand. The technical outlook is bullish, with moving averages supporting an uptrend and key resistance at $533. Recent news highlights surging power demand in South Korea linked to chipmaker expansions and AI data centers, underscoring sector growth catalysts. A 1:3 stock split is scheduled for November 2026, potentially enhancing accessibility.

The ETF's outlook remains positive, fueled by robust AI-driven semiconductor demand and institutional inflows, though risks include potential tariff hikes and market volatility. Analysts are broadly optimistic, citing diversified exposure to top performers like Nvidia and AMD. Investors should weigh near-term overcrowding risks against long-term structural growth in AI and memory markets.